Based on this genotype and phenotype correlation, the American Thyroid association has proposed the classification of four risk-categorized mutations and recommends the screening for PCC by the age of 20 years for MEN2A and by 8 years for MEN2B (18). The gene discussed is RET; the disease is adrenal gland pheochromocytoma.